New diabetes drugs target gut hormones.
Kuehn
Bridget M
BM
D000682:Amyloid / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000188:drug therapy*; D004152:Dipeptidyl-Peptidases and Tripeptidyl-Peptidases / Q000037:antagonists & inhibitors*; D000077270:Exenatide; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D058228:Islet Amyloid Polypeptide; D000069450:Liraglutide; D010455:Peptides / Q000627:therapeutic use; D014688:Venoms / Q000627:therapeutic use
D000682:Amyloid; D007004:Hypoglycemic Agents; D058228:Islet Amyloid Polypeptide; D010455:Peptides; D014688:Venoms; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1; D000077270:Exenatide; C105254:pramlintide; D004152:Dipeptidyl-Peptidases and Tripeptidyl-Peptidases